Community-Acquired Pneumonia Treatment Guidelines

Introduction to Treatment

The American Thoracic Society recommends treatment for community-acquired pneumonia based on patient characteristics, with amoxicillin as first-line therapy for healthy outpatients, combination therapy or respiratory fluoroquinolones for those with comorbidities, and β-lactam plus macrolide or respiratory fluoroquinolone for hospitalized patients 1, 2, 3

The American College of Physicians recommends amoxicillin 1 g three times daily for healthy adults without comorbidities (strong recommendation, moderate quality evidence) 1, 2, 4
The Infectious Diseases Society of America suggests doxycycline 100 mg twice daily for healthy adults without comorbidities (conditional recommendation, low quality evidence) 1, 2
For adults with comorbidities, the American Thoracic Society recommends combination therapy with β-lactam and macrolide, or monotherapy with respiratory fluoroquinolone 1, 2, 5

The American Thoracic Society recommends β-lactam plus macrolide for non-severe community-acquired pneumonia without risk factors for MRSA or P. aeruginosa 6
For severe community-acquired pneumonia without risk factors for MRSA or P. aeruginosa, the American College of Chest Physicians recommends β-lactam plus macrolide (strong recommendation, moderate quality evidence) 6
The Infectious Diseases Society of America suggests β-lactam plus respiratory fluoroquinolone for severe community-acquired pneumonia without risk factors for MRSA or P. aeruginosa (strong recommendation, low quality evidence) 6

The Centers for Disease Control and Prevention recommends considering recent antibiotic exposure when selecting treatment, as patients with recent exposure to one class of antibiotics should receive treatment with antibiotics from a different class due to increased risk for bacterial resistance 6, 7
The American Thoracic Society recommends diagnostic testing for pneumococcal and Legionella urinary antigens in patients with severe community-acquired pneumonia 8, 9

The American College of Physicians recommends using severity assessment tools to guide site-of-care decisions and treatment intensity, and avoiding underestimation of severity 1, 3
The Infectious Diseases Society of America suggests avoiding macrolide monotherapy in areas with pneumococcal resistance ≥25% 1, 2
The American Thoracic Society recommends considering resistant pathogens, including MRSA and P. aeruginosa, when selecting treatment 6, 5

The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicilina-ácido clavulánico 875/125 mg twice daily for 7-10 days for adults with comorbidities and community-acquired pneumonia 10

For adults with comorbilidades, the standard dose of amoxicilina-ácido clavulánico is 875/125 mg twice daily for 7-10 days, according to the American Academy of Otolaryngology-Head and Neck Surgery 10
For patients with moderate disease or recent antibiotic use (within 4-6 weeks), a high-dose formulation of 2000/125 mg twice daily may be considered, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 10

The recommended dose of azithromycin is 500 mg on day 1, followed by 250 mg daily for 4 additional days, according to the Clinical Infectious Diseases journal 11

The American Academy of Otolaryngology-Head and Neck Surgery recommends a treatment duration of 7-10 days for betalactam antibiotics, such as amoxicilina-ácido clavulánico 10
The Clinical Infectious Diseases journal recommends a treatment duration of 3-5 days for macrolide antibiotics, such as azithromycin 11

Patients should be reevaluated after 72 hours, and if there is no improvement or worsening, the treatment should be adjusted, according to the American Academy of Otolaryngology-Head and Neck Surgery and the Clinical Infectious Diseases journal 10, 11, 12

Patients with recent antibiotic use (within 4-6 weeks) are at increased risk of infection with resistant organisms, and high-dose amoxicilina-ácido clavulánico may be considered, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 10
Patients with immunosuppression require special consideration, and the American Academy of Otolaryngology-Head and Neck Surgery recommends adjusting the treatment regimen accordingly 10